Johnson & Johnson Forecasts Profit Growth Despite Drug Pricing Deal | Eli Lilly Invests $6 Billion in Alabama Pharmaceutical Facility | Pfizer Acquires Metsera for $10 Billion Amidst Bidding War | Merck Scraps £1 Billion UK Expansion Amid Investment Concerns | Merck Scraps London Research Center, Citing UK Investment Concerns | AstraZeneca to Invest $50 Billion in the U.S. | Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity | Iran's Plasma Production: A Boost for Healthcare and Economy | Johnson & Johnson Forecasts Profit Growth Despite Drug Pricing Deal | Eli Lilly Invests $6 Billion in Alabama Pharmaceutical Facility | Pfizer Acquires Metsera for $10 Billion Amidst Bidding War | Merck Scraps £1 Billion UK Expansion Amid Investment Concerns | Merck Scraps London Research Center, Citing UK Investment Concerns | AstraZeneca to Invest $50 Billion in the U.S. | Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity | Iran's Plasma Production: A Boost for Healthcare and Economy
Johnson & Johnson (JNJ) has released an optimistic forecast for 2026, projecting sales and profit figures that surpass Wall Street expectations. This positive outlook comes despite facing challenges such as a drug pricing agreement with the...
Image via CNBC
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
